Class / Patent application number | Description | Number of patent applications / Date published |
435373000 | Method of co-culturing cells | 53 |
20080233643 | Differentiation of Cd34 Positive Cell to Megakaryocyte and Multiplication - An object of the present invention is to provide a method for more efficiently differentiating CD34 | 09-25-2008 |
20080254537 | Compositions and Methods for Inducing the Activation of Immature Monocytic Dendritic Cells - The present invention provides methods for inducing the maturation of immature dendritic cells (DC) and for activating those cells without the use of a dendritic cell maturation agent. The activated DC can be used for inducing an antigen specific T cell response. Methods of the invention can also comprise the addition of a directional maturation agent, such as interferon gamma, to induce a Th-I and/or Th-2 bias in the response obtained. The present invention also provides dendritic cell populations useful for activating and for inducing antigen specific T cells. Similarly, activated antigen specific T cell populations, and methods of making the same are provided. | 10-16-2008 |
20080286864 | Choroid Plexus Preparation and Uses Thereof - The present invention is directed to the use of choroid plexus cells and/or choroid plexus conditioned media for enhancing the growth, survival and/or maintenance of function of non-choroid plexus cells grown in long term or short term culture. | 11-20-2008 |
20080318314 | Production from blood of cells of neural lineage - A method including in vitro stimulating a core cell population (CCP) of at least 5 million cells that have a density of less than 1.072 g/ml, and at least 1.5% of which are CD34+CD45−/dim, to differentiate into a neural progenitor/precursor cell population (NPCP). Other embodiments are also described. | 12-25-2008 |
20090011504 | Cultured cell construct which contains spheroids of cultured animal cells and the use thereof - Parenchymal cells are cultivated on cultivated endothelial cells or cultivated fibroblasts which have been separated by a surface of a specific hydrophilic polymer, and which have been patterned. A culture which contains thus formed patterned spheroids of cultivated parenchymal cells is thereby provided by this invention. This culture maintains a function which is specific to the parenchymal cells over a long period of time. | 01-08-2009 |
20090047738 | FEEDER CELL DERIVED FROM TISSUE STEM CELL - It is an object of the present invention to provide a feeder cell with less variation in quality. The present invention relates to a feeder cell derived from a tissue stem and/or progenitor cell. A method of preparation of the feeder cell, a method of preparation of a cultured cell using the feeder cell, and a cell culturing kit are also provided. | 02-19-2009 |
20090068735 | METHODS OF ISOLATING BIPOTENT HEPATIC PROGENITOR CELLS - A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters. These methods of isolating the hepatic progenitors are applicable to any vertebrates including human. The hepatic progenitor cell population is expected to be useful for cell therapies, for bioartificial livers, for gene therapies, for vaccine development, and for myriad toxicological, pharmacological, and pharmaceutical programs and investigations. | 03-12-2009 |
20090186408 | Biocompatible bilayer porous matrix and preparation thereof - The present invention provides a biocompatible bilayer porous matrix and preparation thereof. The bilayer porous matrix is composed of gelatin, chondroitin 6 sulfate, and hyaluronic acid, also, prepared through freeze-drying technique at different temperature and time duration to form varied pore sizes on each layer. The present invention also provides a method of cell culture using the bilayer porous matrix. | 07-23-2009 |
20090221070 | In Vitro Production of a Cell Population Using Feeder Cells - A method for the in vitro production of a cell population P′ from a cell population P, the production requiring the presence of at least one factor which is expressed by feeder cells, wherein a) feeder cells proliferate at a temperature T | 09-03-2009 |
20090233355 | Compositions and methods for culturing embryos and oocytes - The present invention relates to an oocyte and/or embryo culture medium. The medium includes 0.0003 to 750 ng/ml IGF-II, or a variant or analogue thereof, and further includes either or both of 0.01 to 50 μg/ml plasminogen, or a variant or analogue thereof, and 0.01 to 50 μg/ml urokinase plasminogen activator, or a variant or analogue thereof. | 09-17-2009 |
20090233356 | Tissue Engineered Cellular Sheets, Methods of Making and Use Thereof - The disclosure provides methods and compositions to build living tissue covered stents and the like. These tissue coated stents provide a barrier against cell migration to the lumen of the vessel. Since the tissue can surround and envelope the stent, foreign body responses to the stent material are reduced and delayed. The tissue coating is also relatively impermeable to transmural flow, so the wrapped stent can act as a bypass vessel. The tissue is also robust enough to act as a stand alone vessel, without requiring the presence of the metallic stent. These stents can be endothelialized to reduce thrombosis. The genetic modifications described in this disclosure allow for functional organs to be built that express agents that are anti-restenotic or anti-thrombogenic. | 09-17-2009 |
20090275132 | METHOD FOR PURIFYING CARDIOMYOCYTES OR PROGRAMMED CARDIOMYOCYTES DERIVED FROM STEM CELLS OR FETUSES - An object of the present invention is to develop a method for purify cardiomyocytes at a high degree of purification and at a high yield from a cell mixture comprising cardiomyocytes derived from fetuses and stem cells using various features which have not been previously expected to be used for purification of cardiomyocytes or which are newly found, wherein said method is carried out without undergoing any genetic modification or without adding any special proteins or biologically active agents. | 11-05-2009 |
20090298171 | Method and Device for Treating or Selecting Cells - The present invention is directed to a method of treating cells by co-culturing them with activated fibroblasts in order to regulate the growth and/or status of the cells. Fibroblasts are activated by culturing the cells under conditions that induce the cells to adhere to each other to form multicellular aggregates or spheroids. The present invention also provides a device for selecting cells from cell samples, such as bone marrow aspirate, the device comprises said multicellular aggregates. | 12-03-2009 |
20100028997 | Method for culturing mesenchymal stem cell and method for producing biological tissue prosthesis - The purpose is to proliferate a mesenchymal stem cell to a sufficient degree while reducing the amount of blood serum contained in a biological tissue progenitor cell to be grafted, and to efficiently differentiate the mesenchymal stem cell into the biological tissue progenitor cell. There is provided a method for culturing a mesenchymal stem cell, comprising: a first culture step of proliferating a mesenchymal stem cell in a medium containing blood serum; and a second culture step of differentiating the mesenchymal stem cell into a biological tissue progenitor cell in a medium containing blood serum at a lower concentration than that in the medium used in the first culture step. | 02-04-2010 |
20100075418 | METHOD FOR CO-CULTURE OF STEM CELLS AND FEEDER CELLS USING POLYMER MEMBRANE - The present invention relates to a method for co-culture of stem cells using feeder cells, more particularly to a method for culturing stem cells by using a membrane having a number of pores to separate stem cells and feeder cells. In the present invention, the culture condition of stem cells optimized is provided, in which stem cells and feeder cells are cultivated independently in separate spaces while permeating essential substances selectively. The stem cells prepared in the present invention continue to remain indifferent and be supported by feeder cells until needing being sub-cultured. In addition, the stem cells even for therapeutic use can be obtained without any contaminant since not pretreated with a cytostatic agent such as mitomycin or irradiated. Therefore, the method for co-culturing stem cells by using a membrane of the present invention can be widely used for clinical applications. | 03-25-2010 |
20100099186 | Methods, kits, and compositions for stem cell self-renewal - The present invention relates to methods and kits for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods, kits, and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population. | 04-22-2010 |
20100136685 | METHOD FOR TRANSFERRING CELLS TO CARRIERS AND APPLICATION THEREOF - The invention provides a method for transferring cells to carriers, including: (a) providing a hydrophobic cell culture container or a cell culture container coated with a hydrophobic material on a bottom thereof; (b) adding carriers which are more hydrophilic than the hydrophobic cell culture container or hydrophobic materials and a culture medium containing cells into the hydrophobic cell culture container or the cell culture container coated with the hydrophobic material on the bottom thereof; and (c) culturing the cells, wherein the cells attach to the carriers and grow. | 06-03-2010 |
20100304484 | Use of Alginate Matrices to Control Cell Growth - Methods of inhibiting proliferation of a plurality of proliferating cells are disclosed. Methods of inhibiting cell overgrowth on compositions that are in an animal's body are disclosed. Methods of inhibiting cell overgrowth on a device that is in an animal's body are disclosed. Devices that have on their exterior surface an alginate matrix that comprises Strontium are disclosed. Compositions comprising an alginate body and alginate sheets that each comprise a single layer of cells coating the exterior surface of the alginate body are disclosed. Methods of preparing an artificial tissue are disclosed. Devices comprising cells encapsulated within an alginate matrix and/or maintained as a monolayer on an alginate body, and methods of making and using the same are disclosed. Methods of coating compositions and devices are disclosed. | 12-02-2010 |
20110027881 | PRODUCTION METHOD OF IMMUNE CELLS - A production method of T cells is disclosed which includes generating iPS cells from immune cells and differentiating the iPS cells into desired immune cells. In this method, 4 different genes Oct4, Sox2, Klf4 and c-Myc are introduced into immune cells for generation of iPS cells, and the iPS cells are then differentiated into immune cells by coculture with OP9 cells. Source immune cells are taken from a patient, and the produced desired immune cells are injected into the patient for medical treatment. | 02-03-2011 |
20110111500 | 3-Dimensional feeders for single cell co-culture in microarray slides - This invention provides a co-culture method using 3-dimensional feeders to support single cell in microwells of microarray chips. Microbeads are utilized as carrier to manipulate feeders into 3-dimensional layers in a microwell, to retain feeders at desired location, to keep feeders away from single cell at a desired distance, to revive feeders for optimized co-culture, and to eliminate feeders from image background in post imaging analysis. | 05-12-2011 |
20110136228 | METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY - An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm | 06-09-2011 |
20110244567 | Device and Method of 3-Dimensionally Generating IN VITRO Blood Vessels - Provided herein are apparatuses, systems and methods for generating concentration gradients of soluble molecules. Also, provided herein devices and methods for generating in vitro blood vessels. | 10-06-2011 |
20110256626 | METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS WITH HIGH EFFICIENCY AND INDUCED POLURIPOTENT STEM CELLS PROUCED THEREBY - The present invention provides a method for producing customized pluripotent stem cells. Specifically, the present invention comprises following steps: extracting proteins from any of the dedifferentiated stem cells or induced pluripotent stem cells, the said dedifferentiated or pluripotent stem cells being prepared by any known method; introducing the protein extract into the adult somatic cells; and culturing the adult somatic cells to produce pluripotent stem cells having the same pluripotency as that of embryonic stem cells. In addition, pluripotent stem cells produced according to the present method and cell therapeutics comprising the same are provided. The method allows pluripotent stem cells to be produced very easily and at a significantly higher yield, compared to typical methods. | 10-20-2011 |
20110281351 | PROCESS FOR PRODUCING LAMINATED HIGH-DENSITY CULTURED ARTIFICIAL TISSUE, AND LAMINATED HIGH-DENSITY CULTURED ARTIFICIAL TISSUE - Disclosed is a process for producing an artificial tissue, which comprises a step of providing a liquid flow control member and a mesh member in a flow path through which a cell culture liquid comprising at least one type of animal cells, a collagen-binding cell growth factor and an extracellular matrix component is circulated and cultured to accumulate the extracellular matrix molecule and the animal cells on the surface of the liquid flow control member at a high density, thereby forming a high-density cultured tissue, wherein the liquid flow control member and the mesh member are so arranged in the flow path that these members are in contact with each other or in proximity to each other, and wherein the mesh member is arranged on the back side of the liquid flow control member relative to the direction of the liquid flow. Also disclosed is an artificial tissue produced by the process. | 11-17-2011 |
20120009677 | METHOD FOR PRODUCING A BIO-ARTIFICIAL TRANSPLANT - The invention relates to a method for producing a bio-artificial transplant from biological tissue provided for transplantation, which has cells that are compatible with the recipient applied thereto. According to the invention, a controlled tissue generation is carried out in-vitro, during which selected cells that are capable of remodelling the carrier structures are added to native tissue that is maintained in a culture and the culture is continued until a new tissue which has been substantially transformed is obtained, said tissue containing the added recipient-compatible cells. | 01-12-2012 |
20120058557 | Mineralized Three-Dimensional Bone Constructs - The present disclosure provides ex-vivo derived mineralized three-dimensional bone constructs. The bone constructs are obtained by culturing osteoblasts and osteclast precursors under randomized gravity vector conditions. Preferably, the randomized gravity vector conditions are obtained using a low shear stress rotating bioreactor, such as a High Aspect Ratio Vessel (HARV) culture system. The bone constructs of the disclosure have utility in physiological studies of bone formation and bone function, in drug discovery, and in orthopedics. | 03-08-2012 |
20120094383 | METHODS FOR INDUCING CELL DEATH IN PLURIPOTENT STEM CELLS AND DIFFERENTIATED CELLS OTHER THAN CARDIAC MYOCYTES - The present invention has as its object developing a method that does not involve genomic modification and which yet is capable of inducing cell death in pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells, as well as in differentiated cells other than cardiomyocytes derived from pluripotent stem cells, but not in cardiomyocytes. It has been revealed that by establishing a method capable of inducing cell death in cells other than cardiomyocytes in a very efficient manner by adding a substance having no recognized inherent toxicity or cell death inducing action to the culture conditions for pluripotent stem cells and non-cardiomyocytes, the stated problem can be solved without relying upon genomic modification. | 04-19-2012 |
20120208275 | Methods for co-culturing cord blood cells or cord tissue with menstrual multipotent cells - Methods are provided for obtaining expanded human cord blood cells or cord tissue cells expressing CD34. The methods involve seeding a sufficient amount of human cord blood cells or cord tissue cells with a sufficient amount of menstrual cells under co-culture conditions suitable to promote expansion of the cord cells, and co-culturing the cord cells with the menstrual cells under culture conditions that support at least two or more population doublings of the cord cells. Methods are also provided for growing expanded human cord cells to give rise to any one of colony forming units, colony forming unit granulocyte macrophages (CFU-GM), burst forming unit erythroids (BFU-E), and colony forming unit granulocyte erythrocyte macrophage megakaryocyte (CFU-GEMM) blood lineage precursor cells. The expanded cells may express CD34, SSEA-4, and HLA-II. Compositions of the expanded cells are also provided. | 08-16-2012 |
20120244617 | MESH ENCLOSED TISSUE CONSTRUCTS - Described is a scaffold that is strong enough to resist forces that exist inside a body, while possessing biocompatible surfaces. The scaffold is formed of a layer of mesh (e.g., Stainless Steel or Nitinol) that is tightly enclosed by a multi-layer biological matrix. The biological matrix can include three layers, such a first layer (smooth muscle cells) formed directly on the metal mesh, a second layer (fibroblast/myofibroblast cells) formed on the first layer, and a third layer (endothelial cells) formed on the second layer. The scaffold can be formed to operate as a variety of tissues, such as a heart valve or a vascular graft. For example, the mesh and corresponding biological matrix can be formed as leaflets, such that the scaffold is operable as a tissue heart valve. | 09-27-2012 |
20130005035 | METHODS FOR GENERATING T LYMPHOCYTES FROM HEMATOPOIETIC STEM CELLS - This disclosure describes methods for differentiating T cells and NK cells in vitro from hematopoietic stem cells or precursor cells. The technology is directed to methods for the production of selected populations of lymphocytes, such as T cells and NK cells. The availability of such cell populations allows for the complete reconstitution of a depleted, defective or missing lymphocyte population in a patient. | 01-03-2013 |
20130084637 | SINGLE B-CELL CULTIVATION METHOD - Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG | 04-04-2013 |
20130102075 | METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY - An improved method of culturing cells for cell therapy applications that includes growing desired cells in the presence of antigen-presenting cells and/or feeder cells and with medium volume to surface area ratio of up to 1 ml/cm | 04-25-2013 |
20130302890 | STEM CELLS & MATRIX FROM CORD TISSUE - Methods for isolating and culturing stem cells, making tissue matrix, making matrix infused with stem cells, and methods of stem cell therapy are provided. | 11-14-2013 |
20140127803 | iPS CELL HAVING DIFFERENTIATION PROPENSITY FOR CORNEAL EPITHELIUM - A major object of the present invention is to provide a method for inducing cell differentiation into corneal epithelial stem cells and/or corneal epithelial cells, for the easy production of a corneal epithelial cell sheet having superior safety in view of the possibility of vascularization and the like occurring. A method for inducing differentiation of a pluripotent stem cell into a corneal epithelial stem cell and/or a corneal epithelial cell, the method comprising the step of culturing a pluripotent stem cell in the presence of a stromal cell or an amnion-derived factor. | 05-08-2014 |
20140186949 | ENHANCING A POPULATION OF INSULIN RELEASING CELLS USING GFR Alpha-1 Agonists - Provided herein are pharmaceutical and transplant compositions and methods related to the treatment and prevention of diabetes. More specifically, the compositions and methods are related to activation of glial derived neurotrophic factor (GDNF) receptors or overexpression of the GFR-α1/c-Ret receptor complex in insulin secreting cells so as to promote cell survival and proliferation. | 07-03-2014 |
20140308743 | METHOD FOR CULTURING STEM CELL - The present invention provides a method of obtaining aggregates containing a rostral hypothalamus tissue and a rostral head ectodermal tissue, a hypophysis precursor tissue and a hypophysis hormone producing cell, by using a serum-free medium (preferably substantially free of growth factor and insulins), forming homogeneous aggregates of stem cells from pluripotent stem cells such as ES cell and the like, which are plated at a high cell concentration, and subjecting the formed aggregates to floating-culture. | 10-16-2014 |
20140322809 | Use of a Rock Inhibitor to Sustain Primary Human Keratinocytes in a Proliferative State - Disclosed herein is the finding that treatment with a ROCK inhibitor increases proliferation and induces immortalization of primary keratinocytes. Accordingly, provided is a method of immortalizing primary keratinocytes by exposure to a ROCK inhibitor. Also provided are immortalized primary keratinocytes produced by the described method, as well as organotypic tissue equivalents and cell cultures comprising the immortalized primary keratinocytes. Furthermore, ROCK inhibitor-treated cells show a greatly increased ability to support viral DNA replication of both “low risk” and “high risk” HPV genomes, indicating that ROCK inhibitors will be useful for studying the life cycles of a wide range of HPVs. | 10-30-2014 |
20140356952 | DERIVATION OF EMBRYONIC STEM CELLS AND EMBRYO-DERIVED CELLS - This present invention provides novel methods for deriving embryonic stem cells and embryo-derived cells from an embryo without requiring destruction of the embryo. The invention further provides cells and cell lines derived without embryo destruction, and the use of the cells for therapeutic and research purposes. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF. | 12-04-2014 |
20140377864 | Bioengineered Allogeneic Blood Vessel - The present invention relates to methods for recellularization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases. | 12-25-2014 |
20150072422 | METHOD OF ENHANCING PROLIFERATION AND/OR SURVIVAL OF MESENCHYMAL PRECURSOR CELLS (MPC) - The present invention relates to methods of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) and/or progeny derived therefrom in vitro or in vivo comprising exposing the MPC or progeny to SDF-1 or analog thereof. The invention also relates to compositions comprising isolated MPCs or progeny derived therefrom and SDF-1 or analogues thereof. The present invention also relates to using such methods and compositions for ex vivo or in vivo bone formation in mammals. | 03-12-2015 |
20150306145 | ALLOGENIC MESENDRITIC VECTOR FOR OVARIAN CANCER - The present invention recommends a new approach of allogenic dendritic-stem cell vaccine platform to treat all kinds of ovarian cancers. It proposes the abundant allogenic donated cord blood source to harvest both dendritic special type and mesenchymal stem cells equilibrated package primed with patient's tumour antigens for a targeted treatment regime. The individual roles of dendritic cells and mesenchymal stem cells in immunomodulation is exploited in developing this new combinatorial platform of cellular vectors for targeted killing of tumour cells in the patient's body. The source proposed here in developing the technology is a biological discard and is available in profusion for proposed clinical application. | 10-29-2015 |
20150337262 | STANDARDIZED EX VIVO PLATFORMS FOR THE ANTIGEN-SPECIFIC EXPANSION OF CD4+ T CELL POPULATIONS - The invention relates to methods, peptides, nucleic acids and cells for use in isolating and expanding human T cell populations in an antigen-specific manner for immunodiagnostic or therapeutic purposes. The invention also relates to professional antigen presenting cells derived from pluripotent human stem cells, and to customizable antigen presentation by the antigen presenting cells. | 11-26-2015 |
20150361394 | CELL-TO-CELL COMMUNICATION WITHOUT EXCHANGE OF MEDIATING DIFFUSIBLE FACTORS OR USING ANY PHYSICAL CONTACT BETWEEN CELLS - The present invention departs from using traditional modes of cell-to-cell communication and concerns exerting influence on a first cell or cell population by bringing a second cell or cell population into proximity with the first cell population without the use of mediating diffusible factors. Cell to cell communications traditionally occur by way of a variety of mechanisms including, for example, by direct coupling through gap junctions using antigen presentation or using ligand receptor interactions. | 12-17-2015 |
20160002599 | PRODUCTION METHODS FOR MEGAKARYOCYTES AND PLATELETS - An object of the present invention is to provide a method of efficiently producing a maturated megakaryocytic cell line from hematopoietic progenitor cells. The present invention provides a method for producing megakaryocytes from hematopoietic progenitor cells, comprising
| 01-07-2016 |
20160046909 | Use of Apoptotic Cells Ex Vivo to Generate Regulatory T Cells - Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so. The recognition of apoptotic cells (“ACs”) occurs via a series of evolutionarily-conserved, AC associated molecular-pattern receptors (“ACAMPRs”) on APCs that recognize and bind corresponding apoptotic-cell-associated molecular patterns (“ACAMPs”). These receptors recognize ligands such as phosphotidyl serine and oxidized lipids found on apoptotic cells. Savill et al. (2002); and Gregory et al. (2004). | 02-18-2016 |
20160097032 | METHODS OF OBTAINING CELL POPULATIONS ENRICHED WITH DESIRED CELLS - Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III β-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells. | 04-07-2016 |
20160102291 | Dendritic Cell Compositions and Methods - Methods are provided for the production of dendritic cells from monocytes that have been incubated at a temperature of 1° C.-34° C. for a period of approximately 6 to 96 hours from the time they are isolated from a subject. After the incubation period, the monocytes can then be induced to differentiate into dendritic cells. Mature dendritic cells made by the methods of the invention have increased levels of one or more of CD80, CD83, CD86, MHC class I molecules, or MHC class II molecules as compared to mature dendritic cells prepared from monocytes that have not been held at 1° C.-34° C. for at least 6 hours from the time they were isolated from a subject. Dendritic cells made by the methods of the invention are useful for the preparation of vaccines and for the stimulation of T cells. | 04-14-2016 |
20160102293 | DEVICE AND METHOD OF 3-DIMENSIONALLY GENERATING IN VITRO BLOOD VESSELS - Apparatuses, systems, and methods for generating concentration gradients of soluble molecules are disclosed herein. Devices and methods for generating in vitro blood vessels are also disclosed. | 04-14-2016 |
20160145553 | MODULAR PLATFORM FOR MULTI-TISSUE INTEGRATED CELL CULTURE - The systems and methods disclosed herein are generally related to a cell culture system. More particularly, the systems and methods enable the culturing and interconnecting of a plurality of tissue types in a biomimetic environment. By culturing organ specific tissue types within a biomimetic environment and interconnecting each of the organ systems in a physiologically meaningful way, experiments can be conducted on in vitro cells that substantially mimic the responses of in vivo cell populations. In some implementations, the organ systems are fluidically connected with a constant-volume pump. | 05-26-2016 |
20160152951 | REGULATORY B CELLS (tBREGS) AND THEIR USE | 06-02-2016 |
20160160185 | CELL MASS CAPABLE OF SERVING AS A PRIMITIVE ORGAN-LIKE STRUCTURE COMPRISED OF A PLURALITY OF CELL TYPES OF SOMATIC ORIGIN - The present invention provides a method of producing a cell mass capable of serving as a primitive organ-like structure comprised of a plurality of somatic cell types of somatic origin, comprising: preparing cultures containing the plurality of types of somatic cells; mixing the plurality of types of somatic cell cultures followed by adding a Wnt signal activator to the mixed cell culture; subjecting the culture containing the Wnt signal activator to non-plate contact culturing over a predetermined time period; and replacing the medium of the culture cultured by the non-plate contact culturing with medium not containing Wnt signal activator and further culturing for a predetermined time period; wherein, at least one type of the plurality of somatic cells is maintained in an undifferentiated state. | 06-09-2016 |
20160201037 | MODULAR, MICROFLUIDIC, MECHANICALLY ACTIVE BIOREACTOR FOR 3D, MULTI-TISSUE, TISSUE CULTURE | 07-14-2016 |
20170233695 | Cell Culture Media Composition and Methods of Producing Thereof | 08-17-2017 |